Advertisement

Transdermal Scopolamine in the Treatment of Vertiginous Episodes Associated with Ménière’s Disease

  • Takeo Kumoi
  • Toru Inamori
  • Hiroshi Mori

Abstract

The parasympatholytic drugs, the antihistamines, and the phenothiazine tranquilizers all have a central depressant action and have long been used in preventing or treating motion sickness. The most widely used drugs are those with few atropine-like or sedative side-effects and thanks to the interest of the armed forces, many field studies and clinical trials evaluating drugs against motion sickness are available [1, 2]. In 1966, Brand and Perry [3] compiled exhaustive reviews on drugs used in motion sickness. They reported that there is no substitute for l-hyoscine (scopolamine) where the aim is to provide quick action but short-term protection against exposure to severe motion, but that for the prophylaxis of motion sickness during a long voyage, the diphenhydramine, cyclizine, may afford adequate protection.

Keywords

Motion Sickness Vestibular Nucleus Remission Group Aviat Space Environ Scopolamine Hydro Bromide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Graybiel A, Cramer DB, Wood CD (1982) Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat Space Environ Med 53: 770–772PubMedGoogle Scholar
  2. 2.
    Pyykko I, Padoan S, Schalen L, Lyttkens L, Magnusson M, Henriksson NG (1985) The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviat Space Environ Med 56: 777–782PubMedGoogle Scholar
  3. 3.
    Brand JJ, Perry WLM (1966) Drugs used in motion sickness. Pharmacol Rev 18: 895–924PubMedGoogle Scholar
  4. 4.
    Shaw JE, Bayne W, Schmitt LG (1976) Clinical pharmacology of scopolamine. Clin Pharmacol Ther 19: 15–19Google Scholar
  5. 5.
    Wood CD, Graybiel A (1970) Evaluation of antimotion sickness drugs. A new effective remedy revealed. Aerospace Med 41: 932–933Google Scholar
  6. 6.
    Shute CC, Lewis PR (1963) Cholinesterase-containing systems of the brain of the rat. Nature 199: 1160–1164PubMedCrossRefGoogle Scholar
  7. 7.
    Shute CC, Lewis PR (1965) Cholinesterase-containing pathways of the hindbrain. Afferent cerebellar and centrifugal cochlear fibers. Nature 205: 242–246Google Scholar
  8. 8.
    Parrott AC (1989) Transdermal scopolamine. A review of its effects upon motion sickness, psychological performance, and physiological functioning. Aviat Space Environ Med 60: 1–9PubMedGoogle Scholar
  9. 9.
    Balon RW (1983) The dizzy patient. Symptomatic treatment of vertigo. Postgrad Med 73: 317–324Google Scholar
  10. 10.
    Babin RW, Balkany TJ, Fee WE (1984) Transdermal scopolamine in the treatment of acute vertigo. Ann Otol Rhinol Laryngol 93: 25–27PubMedGoogle Scholar
  11. 11.
    Rahko T, Karma P (1985) Transdermal scopolamine for peripheral vertigo (a double-blind study). J Laryngol Otol 99: 653–656PubMedCrossRefGoogle Scholar
  12. 12.
    Lenore G, Schmitt RN, Shaw JE (1986) Alleviation of induced vertigo. Arch Otolaryngol Head Neck Surg 112: 88–91Google Scholar
  13. 13.
    Pyykkò I, Magnusson M, Schalen K, Enbom H (1988) Pharmacological treatment of vertigo. Acta Otolaryngol [Suppl] (Stockh) 455: 77–81CrossRefGoogle Scholar
  14. 14.
    Jaju BP, Kirsten EB, Wang SC (1970) Effects of belladonna alkaloids on vestibular nucleus of the cat. Am J Physiol 219: 1248–1255PubMedGoogle Scholar
  15. 15.
    Kohl RL, Homick JL (1983) Motion sickness, a modulatory role for the central cholinergic nervous system. Neurosci Biobehav Rev 7: 73–85PubMedCrossRefGoogle Scholar
  16. 16.
    Klein BL, Ashenburg CA, Reed MD (1985) Transdermal scopolamine intoxication in a child. Pediatr Emerg Care 1: 208–209PubMedCrossRefGoogle Scholar
  17. 17.
    Wilkinson JA (1987) Side effects of transdermal scopolamine. J Emerg Med 5: 389–392PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1990

Authors and Affiliations

  • Takeo Kumoi
  • Toru Inamori
  • Hiroshi Mori

There are no affiliations available

Personalised recommendations